Program:

Dr. M. Brandao gives an overview of what the term “resectability” means in NSCLC.
Prof. N. Girard presents a resectable NSCLC case treated with neoadjuvant chemoimmunotherapy, from a pneumo-oncologist’s perspective.
Prof. J. Spicer presents 3 different patient cases treated with neoadjuvant chemoimmunotherapy, from a thoracic surgeon’s perspective.

Topics covered:

Consensual definition of stage III NSCLC by the EORTC working group, biomarkers for early stage NSCLC, patient management during neoadjuvant treatment, patient management before-during-after surgery, how to predict pathological complete response, who should receive adjuvant immunotherapy after neoadjuvant chemoimmunotherapy, NSCLC “stage” as a continuous variable.

Program:

Dr. E. Linardou gives an overview of the current treatment options for 1L mNSCLC
Prof. L. Decoster and Dr. W. Theelen cover the treatment decision-making in 1L mNSCLC, by means of learnings from patient cases

Topics covered:

Baseline patient characteristics, treatment decision making for patients diagnosed with metastatic disease or for patients progressing after earlier stage disease treatment, efficacy parameters, management of patients with brain metastases, management of patients with KRAS mutations, management of elderly and/or PS2 patients and patients with auto-immune disease. Management of immune-related adverse events and treatment sequencing.

Program:

Dr. Burgers shares his experience with dual IO in MPM
Prof. Dr. Peeters shares her experience with dual IO in NSCLC

Topics covered:

Efficacy parameters, management of syndrome of inappropriate antidiuretic hormone and adrenal insufficiency, management of rash grade 1–2, second-line treatment options in mNSCLC, management of patients with brain metastases, treatment discontinuations and immune-mediated adverse events and quality of life.

Program:

Prof. Dr. Scherpereel shares his experience with dual IO in MPM
Prof. Dr. Reck shares his experience with dual IO in NSCLC

Topics covered:

Efficacy parameters, pulmonary immune related adverse events, management of hyperthyreosis, integrating the patient in treatment decision making, maintaining normality for patients whilst receiving treatment, patient selection for dual immunotherapy regimens, communicating to the patient on treatment options and rationale for treatment selection as well as rationale for discontinuation of immunotherapy, management of immune-mediated adverse reactions, rechallenging and treatment sequencing.

Program:

Dr. Talbot presents a case on MPM
Dr. Linardou presents a case on mNSCLC

Topics covered:

Management of immune related hepatitis, efficacy parameters in both lung and brain, as well as management of hypophysitis, rationale and patient selection for dual immunotherapy vs monotherapy in NSCLC, duration of treatment and stopping after two years in NSCLC & mesothelioma, strategies for discontinuing treatment due to toxicities, rechallenging in NSCLC, second-line treatment options, and patient education with regards to immune-mediated adverse events.

Program:

Prof. Dr. Baas shares his experience with dual IO in MPM
Prof. Dr. Paz-Ares shares his experience with dual IO in NSCLC

Topics covered:

Efficacy parameters, management of hepatotoxicity, nephritis and diarrhea, rationale for treatment regimen in CM-743, quality of life on particular arms in CM-743 for patients with mesothelioma, treatment discontinuation after immune-mediated adverse events as well as re-challenge, managing patients with brain metastases and use of immunosuppressants with immunotherapy for safety management.

Program:

Prof. Dr. Coulie discusses the mechanism of action of dual IO
Prof. Dr. Larkin shares his experience with dual IO in Renal Cell Carcinoma
Prof. Dr. Demedts shares his experience with dual IO in NSCLC

Topics covered:

Rationale for adding chemotherapy to dual I-O as well as the type of chemotherapy, mechanism behind anti-CTLA4 safety profile and the dose-dependent relationship key properties of T cells for cancer therapy, the role of CTLA-4 and PD-1 checkpoints on T cells, treatment duration, proposed mechanisms for irAEs, management of uveitis, polyarthralgia, diarrhea, skin toxicities, as well as efficacy parameters and key recommendations for pulmonologists who are new to anti-CTLA4 inhibition.

Program:


Prof. Dr. Beuselinck shares his experience with dual IO in Renal Cell Carcinoma
Dr. Labots shares her experience with dual IO in Melanoma
Prof. Dr. Bennouna shares his experience with dual IO in NSCLC

Topics covered:

Management of fatigue & adrenalitis, brain metastases, management of diarrhea & balanitis, efficacy parameters and safety outcomes.